Abbreviations
- ABL:
-
„Abelson murine leukemia viral oncogene“
- ALK:
-
„Anaplastic lymphoma kinase“
- BCR:
-
„Breakpoint cluster region protein“
- BRAF:
-
„v-raf murine sarcoma viral oncogene homolog B1“
- FGFR3:
-
„Fibroblast growth factor receptor 3“
- GDP:
-
„Guanosine diphospat“
- GTP:
-
„Guanosine triphosphate“
- MAP2K1:
-
„Mitogen-activated protein kinase“
- MET:
-
„Mesenchymal epithelial transition factor“
- NF1:
-
„Neurofibromatosis type 1“
- NRAS:
-
„Neuroblastoma RAS viral oncogene homolog“
- PTEN:
-
„Phosphatase and tensin homolog“
- RET:
-
„Rearranged during transfection“
- RAF1:
-
„Rapidly accelerated fibrosarcoma“
Literatur
Riely GJ, S‑HI O, Rybkin I et al (2021) KRYSTAL-1: activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients with advanced non-small cell lung cancer (NSCLC) harboring KRASG12C mutation. J Thorac Oncol 16(suppl_4):S748-S802.
Skoulidis F, Li BT, Dy GK et al (2021) Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med 384:2371–2381
Hong DS, Fakih MG, Strickler JH et al (2020) KRASG12C inhibition with sotorasib in advanced solid tumors. N Engl J Med 383:1207–1217
Nassar AH, Adib E, Kwiatkowski DJ (2021) Distribution of KRASG12C somatic mutations across race, sex, and cancer type. N Engl J Med 384:185–187
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
A. Gassa, F. Özkan, D. Ast, T. Wahlers, C. Bruns und H. Alakus geben an, dass kein Interessenkonflikt besteht.
Additional information
QR-Code scannen & Beitrag online lesen
Rights and permissions
About this article
Cite this article
Gassa, A., Özkan, F., Ast, D. et al. Resistenzmechanismen beim KRAS-G12C-mutierten Karzinom. Onkologe 27, 1243–1244 (2021). https://doi.org/10.1007/s00761-021-01038-y
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00761-021-01038-y